Bleselumab

Names

[ Name ]:
Bleselumab

Biological Activity

[Description]:

Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

CD40[1]

[In Vitro]

Bleselumab (0-1 μg/mL，48 h) 剂量依赖性地抑制可溶性 CD154 诱导的 PBMCs 增殖[2]。 Cell Viability Assay[2] Cell Line: PBMCs Concentration: 0-1 μg/mL Incubation Time: 48 h Result: Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples.

[In Vivo]

Bleselumab (0.1-10mg/kg，静脉注射) 抑制食蟹猴的迟发型超敏反应 (DTH)[2]。 Bleselumab (2 mg/kg，静脉注射) 可延长食蟹猴移植肾的存活时间[3]。 Bleselumab (2 或 5 mg/kg，静脉注射) 与 Tacrolimus (HY-13756) 联用显示比单一疗法更长的中位生存时间 (MST)[3]。 Animal Model: Cynomolgus monkeys[2]. Dosage: 0.1, 1 and 10 mg/kg Administration: Intravenous injection (i.v.) Result: Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner.

[References]

[1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.

[2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.

[3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.